


Product Data Sheet

RAF265

Cat. No.:	A8313
CAS No.:	927880-90-8
Formula:	C ₂₄ H ₁₆ F ₆ N ₆ O
M.Wt:	518.43
Synonyms:	CHIR-265;RAF 265;RAF-265;CHIR265
Target:	Tyrosine Kinase
Pathway:	VEGFR
Storage:	Store at -20°C



Solvent & Solubility

≥25.9 mg/mL in DMSO; insoluble in H₂O; ≥7.97 mg/mL in EtOH with ultrasonic

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	Concentration			
	1 mM	1.9289 mL	9.6445 mL	19.2890 mL
	5 mM	0.3858 mL	1.9289 mL	3.8578 mL
	10 mM	0.1929 mL	0.9645 mL	1.9289 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Multiple intracellular kinases inhibitor

IC₅₀ & Target

3-60 nM (B-Raf), 30 nM (EC₅₀) (VEGFR2)

In Vitro

Cell Viability Assay

Cell Line:	A549, HCT116, HT29 and MDAMB231 cancer cell lines
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.
Reacting conditions:	5 μM

	Applications:	In all cell lines, RAF265 induced a decrease in clonogenic survival. In A549 cells, the combination of RAD001 and RAF265 enhanced the antiproliferative effect of RAF265.
In Vivo	Animal experiment	
	Animal models:	Mice bearing H460 xenografts
	Dosage form:	12 mg/kg, p.o.; q.d.
	Applications:	In mice bearing H460 xenografts, RAD001 and RAF265 given alone showed limited effect on inhibition of tumor growth. When combined with RAD001, RAF265 significantly delayed tumor growth.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Mordant P, Lorient Y, Leteur C, Calderaro J, Bourhis J, Wislez M, Soria JC, Deutsch E. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9(2):358-68.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

